Meng‐Chih Lin

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.7K citations · Full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Suresh S. Ramalingam, Yi Cheng, C. Zhou et al. · Annals of Oncology · 2018 · 352 citations · Full text

Biology, Physiology, Preliminary Data +1

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng et al. · Nature Communications · 2023 · 214 citations · Full text

Baseline Egfrm, Met Amplification, Medicine +15

Endobronchial Ultrasonography-Guided Transbronchial Needle Aspiration Increases the Diagnostic Yield of Peripheral Pulmonary Lesions

Tung-Ying Chao, Min-Te Chien, Chien-Hao Lie et al. · CHEST Journal · 2008 · 137 citations

Peripheral Pulmonary Lesions, Medical Imaging, Pneumothorax +12